The possibilities of molecular testing of somatic aberrations in tumor tissue using NGS in routine practice - current situation in the Czech Republic

Autor: Pavel, Dundr, Radoslav, Matěj, Aleš, Ryška, Jana, Prausová, Jindřich, Fínek, Luboš, Petruželka, Ivana, Stružinská

Publikováno v: Ceskoslovenska patologie. 57(3)

Molecular testing of tumor tissue for the detection of somatic aberrations using NGS is increasingly gaining significance in routine practice. The technical aspects of testing are standardized and currently do not pose a problem. However, the situati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3b156dc984e284fd89103d8fe04304e9
https://pubmed.ncbi.nlm.nih.gov/34551562

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL)

Autor: Zev A. Wainberg, David Ferry, Ravindranath Patel, Denis Pezet, Elzbieta Wojcik, Kazumasa Fujitani, Vera Gorbounova, Fernando Cabanillas, Bela Piko, Fidel David Huitzil Melendez, Agnes Ruzsa, Jean-Marc Phelip, Madhuri Bajaj, J.T. Beck, Elizabeth Won, Alexander Luft, Sara Lonardi, Peter C. Enzinger, Maen A. Hussein, Bohuslav Melichar, Daisuke Sakai, Angel Gomez Villanueva, A Madi, Georgina Garnica Jaliffe, Carlo Barone, Guillermo Mendez, Marina N. Nechaeva, György Bodoky, Hubert Ayala, Francesco Di Costanzo, Julien Taieb, David H. Ilson, Leslie Samuel, Ronald L. Burkes, Mayukh Das, Marc Van den Eynde, Charles S. Fuchs, Scott M. Berry, Ji Lin, Shuichi Hironaka, Christina Maria Gomez, Thierry Alcindor, Eric Van Cutsem, James A. Jr Reeves, Katriina Peltola, Timothy R. Asmis, Christine Brezden-Masley, Udit Verma, Javier Gallego Plazas, Isabelle Sinapi, Peter Bono, Nozomu Machida, Cynthia Coo Chua, Francisco Javier Ramirez Godinez, Annemieke Cats, Raija Kallio, Alex Beny, Hiroki Hara, Cardellino Giovanni Gerardo, Diego Lucas Kaen, Wasat Mansoor, Miguel Angel Escudero, Andràs Csilla, Akihito Tsuji, Ralf-Dieter Hofheinz, Jana Pribylova, Marianne Nordsmark, Daniel Dammrich, Maria Alejandra Bartoli, Joanna Pikiel, Robert Andrew Dichmann, Maria Di Bartolomeo, Ricardo Villalobos Valencia, Jill Lacy, Raymond Jang, Carlos Alberto Hernandez, Giuseppe Aprile, Nina A. Karaseva, Jonathan Wadsley, Ian Chau, Svetlana Protsenko, Jana Prausová, Maria Błasińska-Morawiec, Salah-Eddin Al-Batran, Hélène Senellart, Stephen Leong, Francisco Gutiérrez Delgado, Johanna C. Bendell, Laurent Mineur, M.I. Grootscholten, Hugo Ford, Russell D. Petty, Laura Visa Turmo, Roberto Carlesi, Hector Velez-Cortez, Maria Alsina, Jiri Petera, Seigo Yukisawa, Federico Longo Munoz, Mette Karen Yilmaz, Pilar Garcia Alfonso, Baruch Brenner, Irfan Firdaus, William E. Lawler, Sylvie Lorenzen, Moustapha Tehfe, Kohei Shitara, Naotoshi Sugimoto, Karen Geboes, A.J. Ten Tije, Walid Shaib, Shigenori Kadowaki, Nicolas Robert Maisey, H.M.W. Van Laarhoven, Radka Obermannova, F.L.G. Erdkamp, Rubén Dario Kowalyszyn, Joanna Wojcik-Tomaszewska, Peter Istvan Acs, Crystal S. Denlinger, Ravit Geva, Srinivasan Madhusudan, Brian Anthony DiCarlo, Ferdinando De Vita, Alejandro Molina Alavez, Gunnar Folprecht, Kensei Yamaguchi, Moses Sundar Raj, Judit Kocsis, Susanna Hegewisch-Becker, Joana Vidal Barrull, Daisuke Takahari, Tomasz Sarosiek, Luis Fein, Mohamed Hebbar, Tibor Csoszi, Manish A. Shah, Alfredo Falcone, Hugo Hool, Michel Ducreux, Per Pfeiffer, Einat Shacham-Shmueli, Howard J. Lim, Taito Esaki

Publikováno v: The Lancet Oncology, 20(3), 420-435. Lancet Publishing Group

Summary Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e40b7f9384317e149edcc0dc8725d0
https://doi.org/10.1016/s1470-2045(18)30791-5

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Autor: Vladimír Vondráček, Alexander Grebenyuk, Jana Prausová, Tomáš Doležal, M. Navrátil, Alexandra Haas, Kateřina Dědečková, Pavel Vítek, Michal Andrlik, Silvia Sláviková, Stěpan Vinakurau, Barbora Ondrová, Barbora Velacková, Jiří Kubeš, Jozef Rosina

Publikováno v: International journal of radiation oncology, biology, physics. 110(4)

Purpose To analyze the 5-year biochemical disease-free survival (bDFS) and late toxicity profile in patients with prostate cancer treated with pencil beam scanning (PBS) proton radiation therapy. Methods and Materials Between January 2013 and March 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef8240b7cb70828fdfac0fc292fc6781
https://pubmed.ncbi.nlm.nih.gov/33587990

Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

Autor: Takayuki Yoshino, Ling Yang, Pilar García-Alfonso, Allen Lee Cohn, Philip Clingan, F. Nasroulah, Jonathon Polikoff, Volker Heinemann, Lisa O’Brien, Eric Van Cutsem, David Craig Portnoy, Kentaro Yamazaki, Jana Prausová, Rocio Garcia-Carbonero, Josep Tabernero, György Bodoky, Tudor Ciuleanu, Ling Gao, David Ferry, Sara Lonardi, Radka Obermannova

Publikováno v: Cancer Chemotherapy and Pharmacology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Purpose To characterize ramucirumab exposure–response relationships for efficacy and safety in patients with metastatic colorectal cancer (mCRC) using data from the RAISE study. Methods Sparse pharmacokinetic samples were collected; a population ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ae755a5849ab8f5cceec01e6bdf5de
http://europepmc.org/articles/PMC5573752

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp)

Autor: Tanios Bekaii-Saab, Frank Beier, Svenja Adrian, Josep Tabernero, Elena Elez, Jana Prausová, Cindy Neuzillet, Zev A. Wainberg, Eva Liu, Kanwal Pratap Singh Raghav, Filippo Pietrantonio, Stephen Falk, Shaista Salim, Nicole Campbell, Salvatore Siena, Eric Van Cutsem, Nicolas Isambert, Regina Esser

Publikováno v: Journal of Clinical Oncology. 39:TPS149-TPS149

TPS149 Background: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired resistance to anti-EGFR therapy, which can contribute to disease progression. In EGFR-resistant pts with mCRC and METamp, MET inhibition + an anti-E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2dfe19dbcbcff9cdebd8f30f7a166cc9
https://doi.org/10.1200/jco.2021.39.3_suppl.tps149